Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 21;19(11):1648-1659.
doi: 10.7150/ijms.75915. eCollection 2022.

Normalisation of High Bone Remodelling due to Oestrogen Deficiency by Traditional Chinese Formulation Kang Shuai Lao Pian in Ovariectomised Rats

Affiliations

Normalisation of High Bone Remodelling due to Oestrogen Deficiency by Traditional Chinese Formulation Kang Shuai Lao Pian in Ovariectomised Rats

Sophia Ogechi Ekeuku et al. Int J Med Sci. .

Abstract

Postmenopausal osteoporosis transpires due to excessive osteoclastic bone resorption and insufficient osteoblastic bone formation in the presence of oestrogen insufficiency. Kang Shuai Lao Pian (KSLP) is a red ginseng-based traditional Chinese medicine known for its anti-ageing properties. However, studies on its effect on bone loss are lacking. Thus, the current study examined the skeletal protective effects of KSLP in an ovariectomised rodent bone loss model. Three-month-old female Sprague Dawley rats (n=42) were randomised into baseline, sham and ovariectomised (OVX) groups. The OVX rats were supplemented with low- (KSLP-L; 0.15 g/kg), medium- (KSLP-M; 0.30 g/kg), high-dose KSLP (KSLP-H; 0.45 g/kg) or calcium carbonate (1% w/v). The daily supplementation of KSLP was performed via oral gavage for eight weeks. Gavage stress was stimulated in the ovariectomised control with distilled water. The rats were euthanised at the end of the study. Whole-body and femoral bone mineral content and density scans were performed at baseline and every four weeks. Blood samples were obtained for the determination of bone remodelling markers. Histomorphometry and biomechanical strength testing were performed on femurs and tibias. High bone remodelling typically due to oestrogen deficiency, indicated by the elevated bone formation and resorption markers, osteoclast surface, single-labelled surface and mineralising surface/bone surface ratio, was observed in the untreated OVX rats. Whole-body BMD adjusted to body weight and Young's modulus decreased significantly in the untreated OVX rats. High-dose KSLP supplementation counteracted these degenerative changes. In conclusion, KSLP improves bone health by normalising bone remodelling, thereby preventing bone loss and decreased bone strength caused by oestrogen deficiency. Its anti-osteoporosis effects should be validated in patients with postmenopausal osteoporosis.

Keywords: Traditional Chinese medicine; postmenopausal osteoporosis; skeletal health.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Body weight (A), fat mass (B), fat percentage (C), bone mineral content (D), bone mineral density (E) and whole-body bone mineral density/body weight (F) of each study group (n=6/group) during the experiment. The data are expressed as mean ± standard error mean. Mixed-design ANOVA is used to analyse the time and group differences. ap < 0.05 vs sham, bp < 0.05 vs OVX control, cp < 0.05 vs CaCO3, ep < 0.05 vs KSLP-M within the same month; *p < 0.05 vs M0, #p < 0.05 vs M1 within the same group. Abbreviations: CaCO3, calcium carbonate; KSLP-L, KSLP-low dose; KSLP-M, KSLP-medium dose; KSLP-H, KSLP-high dose; OVX, ovariectomised or negative; M0, month 0; M1, month 1; M2, month 2; %, percentage; BMD, bone mineral density.
Figure 2
Figure 2
Osteocalcin (A) and CTX-1 (B) concentration of each study group (n=6/group) before and after the experiment. The data are expressed as mean ± standard error mean. Mixed-design ANOVA is used to analyse the time and group differences. ap < 0.05 vs sham; bp < 0.05 vs OVX control; cp < 0.05 vs CaCO3; dp < 0.05 vs KSLP-L; ep < 0.05 vs KSLP-M with the same time; *p < 0.05 vs before treatment in same group. Abbreviations: CaCO3, calcium carbonate; KSLP-L, KSLP-low dose; KSLP-M, KSLP-medium dose; KSLP-H, KSLP-high dose; OT/BGP, Osteocalcin/Bone Gla protein; OVX, ovariectomised or negative; CTX-1, Type I collagen cross-linked c-telopeptide.
Figure 3
Figure 3
Micrograph of femur sections (100 × magnification) stained using the von Kossa method/silver nitrate (A-G) for each group (n=6/group). The structural histomorphometric indices of the femur evaluated are BV/TV (H), Tb.Th (I), Tb.N (J), and Tb.Sp (K). The quantitative data are expressed as mean ± standard error mean. The differences between groups are evaluated by one-way ANOVA with Tukey's post hoc test. Abbreviations: CaCO3, calcium carbonate; KSLP-L, KSLP-low dose; KSLP-M, KSLP-medium dose; KSLP-H, KSLP-high dose; OVX, ovariectomised or negative; BV/TV, bone volume/total volume; Tb.Th., trabecular bone thickness; Tb.N, trabecular bone number; Tb.Sp., trabecular bone separation
Figure 4
Figure 4
Micrograph of H & E- (A-G) (100 × magnification) and TRAP-stained (H-N) (100 × magnification) femur sections for each study group (n=6/group). Static histomorphometric indices of femur bone evaluated are Ob.S/BS (O), Oc.S/BS (P), ES/BS (Q), OS/BS (R) and OV/BV (S). The data are expressed as mean ± standard error mean. The differences between groups are evaluated by one-way ANOVA with Tukey's post hoc test. ap < 0.05 vs baseline; bp < 0.05 vs sham; cp < 0.05 vs OVX control. Abbreviations: CaCO3, calcium carbonate; KSLP-L, KSLP-low dose; KSLP-M, KSLP-medium dose; KSLP-H, KSLP-high dose; Ob.S/BS, osteoblast surface; Oc.S/BS, osteoclast surface; OVX, ovariectomised or negative; ES/BS, eroded surface; OS/BS, osteoid surface; OV/BS, osteoid volume; Ob, osteoclast; Oc, osteoclast; ES, eroded surface; OS, osteoid
Figure 5
Figure 5
Micrograph of calcein-labelled femur sections (A-G) (200 × magnification) for each study group (n=6/group); Dynamic histomorphometric indices of femur bone evaluated are sLS/BS (H), dLS/BS (I), MS/BS (J), MAR (K) and BFR (L). The data are expressed as mean ± standard error mean. One-way ANOVA with Tukey's post hoc test is used to compare the difference between groups. ap < 0.05 vs baseline; bp < 0.05 vs sham; cp < 0.05 vs OVX control. Abbreviations: CaCO3, calcium carbonate; KSLP-L, KSLP-low dose; KSLP-M, KSLP-medium dose; KSLP-H, KSLP-high dose; OVX, ovariectomised or negative; sLS/BS, single-labelled surface; dLS/BS, doubled-labelled surface; MS/BS, mineralizing surface; MAR, mineral apposition rate; BFR, bone formation rate
Figure 6
Figure 6
Bone mechanical strength indices of each group (n=6/rats) evaluated based on three-point-bending test. The parameters generated are load (A), displacement (B), stiffness (C), stress (D), strain (E) and Young's modulus (F). The data are expressed as mean ± standard error mean. One-way ANOVA with Tukey's post hoc test is used to compare the difference between groups. bp < 0.05 vs sham. Abbreviations: CaCO3, calcium carbonate; KSLP-L, KSLP-low dose; KSLP-M, KSLP-medium dose; KSLP-H, KSLP-high dose; OVX, ovariectomised or negative.

Similar articles

Cited by

References

    1. Mohamad NV, Ima-Nirwana S, Chin KY. Are Oxidative Stress and Inflammation Mediators of Bone Loss Due to Estrogen Deficiency? A Review of Current Evidence. Endocr Metab Immune Disord Drug Targets. 2020;20:1478–87. - PMC - PubMed
    1. Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT. et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2:16069. - PubMed
    1. Lorentzon M, Johansson H, Harvey NC, Liu E, Vandenput L, McCloskey EV. et al. Osteoporosis and fractures in women: the burden of disease. Climacteric. 2022;25:4–10. - PubMed
    1. Kanis JAA, Cooper C, Rizzoli R, Reginster JYY, Clinical obotSABotESf, Economic Aspects of O. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30:3–44. - PMC - PubMed
    1. Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374:254–62. - PubMed